StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.46−0.09 (-15.97%)

Close on Nov 17, 2026Market cap $830.71KP/E –Yield –

Aptevo Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Aptevo Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.20M, up 9.0% year over year. For fiscal 2025 it was $14.54M, up 1.1% from the year before. Over ten years it grew -8.3% a year on average. The highest annual figure on record is $35.39M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.54M+1.1%
FY2024Dec 31, 2024$14.38M-16.0%
FY2023Dec 31, 2023$17.11M-4.3%
FY2022Dec 31, 2022$17.88M-5.9%
FY2021Dec 31, 2021$18.99M+6.4%
FY2020Dec 31, 2020$17.85M-27.9%
FY2019Dec 31, 2019$24.76M-30.0%
FY2018Dec 31, 2018$35.39M+21.9%
FY2017Dec 31, 2017$29.02M-0.3%
FY2016Dec 31, 2016$29.12M-16.1%
FY2015Dec 31, 2015$34.73M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.70M+11.1%
Q1 FY2026Mar 31, 2026$3.92M+8.0%
Q4 FY2025Dec 31, 2025$3.54M-8.9%
Q3 FY2025Sep 30, 2025$4.04M+30.3%
Q2 FY2025Jun 30, 2025$3.33M-8.6%
Q1 FY2025Mar 31, 2025$3.63M-3.2%
Q4 FY2024Dec 31, 2024$3.88M+8.0%
Q3 FY2024Sep 30, 2024$3.10M-20.2%
Q2 FY2024Jun 30, 2024$3.64M-33.3%
Q1 FY2024Mar 31, 2024$3.75M-10.0%
Q4 FY2023Dec 31, 2023$3.59M-23.2%
Q3 FY2023Sep 30, 2023$3.89M-13.2%
Q2 FY2023Jun 30, 2023$5.46M+41.3%
Q1 FY2023Mar 31, 2023$4.17M-14.3%
Q4 FY2022Dec 31, 2022$4.67M+2.9%
Q3 FY2022Sep 30, 2022$4.48M+2.5%
Q2 FY2022Jun 30, 2022$3.87M-18.1%
Q1 FY2022Mar 31, 2022$4.87M-9.3%
Q4 FY2021Dec 31, 2021$4.54M-7.5%
Q3 FY2021Sep 30, 2021$4.37M-2.8%
Q2 FY2021Jun 30, 2021$4.72M+6.4%
Q1 FY2021Mar 31, 2021$5.36M+33.8%
Q4 FY2020Dec 31, 2020$4.91M+11.4%
Q3 FY2020Sep 30, 2020$4.49M-40.8%
Q2 FY2020Jun 30, 2020$4.44M-27.5%
Q1 FY2020Mar 31, 2020$4.01M-39.6%
Q4 FY2019Dec 31, 2019$4.41M-50.5%
Q3 FY2019Sep 30, 2019$7.60M-11.4%
Q2 FY2019Jun 30, 2019$6.13M-36.9%
Q1 FY2019Mar 31, 2019$6.63M-19.1%
Q4 FY2018Dec 31, 2018$8.90M-3.1%
Q3 FY2018Sep 30, 2018$8.57M+19.5%
Q2 FY2018Jun 30, 2018$9.71M+43.1%
Q1 FY2018Mar 31, 2018$8.20M+39.6%
Q4 FY2017Dec 31, 2017$9.19M+44.4%
Q3 FY2017Sep 30, 2017$7.18M+1.4%
Q2 FY2017Jun 30, 2017$6.79M–
Q1 FY2017Mar 31, 2017$5.87M–
Q4 FY2016Dec 31, 2016$6.36M–
Q3 FY2016Sep 30, 2016$7.08M–

More Aptevo Therapeutics figures

See a number that looks wrong?